Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia
Pediatric Blood & Cancer · 2026-08 · 73 (8)
DOI: 10.1002/1545-5017.70395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 14.05.2026. Verfasst von Janna R Shapiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: COVID-19 Immunity Task Force (Public Health Agency of Canada, the Canadian Immunization Research Network, the University of Toronto. A.C.G. holds the Canada Research Chair in Functional Proteomics.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL. Procedure We recruited children with ALL, mostly in the maintenance phase of chemotherapy, and healthy controls who were infected and/or vaccinated with SCV2. Antibody concentrations and avidity against the SCV2 spike (S) protein and its receptor‐binding domain (RBD) were measured, as were the frequencies of S‐specific cytokine‐positive T cells and the concentrations of secreted cytokines.
Results
Antibody levels and avidity were lower in children with ALL than in healthy controls, regardless of when exposure occurred relative to ALL diagnosis. Among children with ALL, vaccination generated greater anti‐RBD antibody levels than infection. Three or more vaccine doses were associated with more robust and higher avidity responses, similar to those of the healthy controls. Antibody levels were more durable in vaccinated children with ALL compared to unvaccinated children. T‐cell responses were similar in healthy controls and children with ALL, although children with ALL showed decreases in the secretion of some cytokines. Among children with ALL, T‐cell responses did not differ by vaccination status and were stable over time.
Conclusions
We identified a significant serological benefit of SCV2 vaccination relative to infection, in terms of antibody avidity, level, and durability. These data can support clinicians in making evidence‐based vaccine recommendations for children with ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
- Center for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada.
- The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
- Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
- Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Janna R Shapiro, Sumit Gupta, Shelly Bolotin, Tania H Watts
Förderung
- COVID-19 Immunity Task Force (Public Health Agency of Canada
- the Canadian Immunization Research Network
- the University of Toronto. A.C.G. holds the Canada Research Chair in Functional Proteomics
Zitieren
APA
Shapiro, J. R., Qi, F., Colwill, K., Dorogy, A. D., Liu, Y., Science, M., Gingras, A. C., Rini, J. M., Gupta, S., Alexander, S., Bolotin, S., & Watts, T. H. (2026). Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70395
Vancouver
Shapiro JR, Qi F, Colwill K, Dorogy AD, Liu Y, Science M, et al. Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70395
BibTeX
@article{Shapiro2026,
author = {Shapiro, Janna R and Qi, Freda and Colwill, Karen and Dorogy, Alina D and Liu, Ying and Science, Michelle and Gingras, Anne-Claude and Rini, James M and Gupta, Sumit and Alexander, Sarah and Bolotin, Shelly and Watts, Tania H},
title = {Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {8},
doi = {10.1002/1545-5017.70395}
}
EUVIMED